Mon panier

CLEC4C

CLEC4C Informations sur la molécule

Nom anglaisC-Type lectin domain family 4 member CNombre de médicaments commercialisés0
Nombre de médicaments cliniques9Alias de la cibleDLEC,HECL,C-type lectin superfamily member 7,CLEC4C,BDCA2,UNQ9361/PRO34150,C-type lectin domain family 4 member C,Dendritic lectin,C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 7,C-Type Lectin Domain Family 4, Member C,CLECSF11,CLECSF7,BDCA-2,C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 11,Blood Dendritic Cell Antigen 2 Protein,Blood Dendritic Cell Antigen 2,Dendritic Cell Lectin B,CD303 Antigen,PRO34150,CD303
Phase de R&D la plus avancéePhase 3 Clinical
Nom anglaisC-Type lectin domain family 4 member C
Alias de la cibleDLEC,HECL,C-type lectin superfamily member 7,CLEC4C,BDCA2,UNQ9361/PRO34150,C-type lectin domain family 4 member C,Dendritic lectin,C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 7,C-Type Lectin Domain Family 4, Member C,CLECSF11,CLECSF7,BDCA-2,C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 11,Blood Dendritic Cell Antigen 2 Protein,Blood Dendritic Cell Antigen 2,Dendritic Cell Lectin B,CD303 Antigen,PRO34150,CD303
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques9
Phase de R&D la plus avancéePhase 3 Clinical

CLEC4C Liste de produits

  • Attribut

    Protein (6)

  • Bibliothèque de produits

    En ligne (6)

  • Espèces

    Human (3)Cynomolgus (3)

  • Étiquette

    Fc Tag (2)His Tag (2)His Tag & Avi Tag (2)

  • Marqueur

    Unconjugated (4)Biotin-labeled (2)

CLEC4CContexte de la molécule

CLEC4C (C-type lectin domain family 4 member C), also known as BDCA2, CLECSF11, CLECSF7, DLEC and CD303. Lectin-type cell surface receptor which may play a role in antigen capturing by dendritic cell. Specifically recognizes non-sialylated galactose-terminated biantennary glycans containing the trisaccharide epitope Gal(beta1-3/4)GlcNAc(beta1-2)Man. Binds to serum IgG. Efficiently targets ligand into antigen-processing and peptide-loading compartments for presentation to T-cells. May mediate potent inhibition of induction of IFN-alpha/beta expression in plasmacytoid dendritic cells. May act as a signaling receptor that activates protein-tyrosine kinases and mobilizes intracellular calcium.

CLEC4CAlias de la molécule

DLEC,CLEC4C,BDCA-2,CD303,CLECSF11,CLECSF7, HECL

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
LitifilimabBIIB-059Phase 3 ClinicalBiogen IncLupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
SSGJ-626SSGJ-626; 626Phase 2 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co LtdLupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
DB-2304DB-2304Phase 2 ClinicalDuality Biologics (Suzhou) Co LtdAutoimmune Diseases; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
ANB-101CBS-004; ANB101Phase 1 ClinicalCapella Bioscience LtdInflammation; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Scleroderma, Systemic
Details
BCD-256BCD-256Phase 1 ClinicalBIOCAD JSCLupus Erythematosus, Systemic
Details
GB-19GB-19; GB19Phase 1 ClinicalShandong Kexing Bio-Products Co LtdLupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
Recombinant anti-BDCA2 humanized monoclonal antibody (Sansheng Guojian)Phase 1 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co LtdLupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
HC-022HC-022; HC022Phase 1 ClinicalShanghai Hongcheng Pharmaceutical Co LtdLupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
LBL-047DNTH-212; LBL-047; DNTH212Phase 1 ClinicalNanjing Leadsbiolabs Co LtdAutoimmune Diseases; Lupus Erythematosus, Systemic
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments cliniques